SOMATULINE Drug Patent Profile
✉ Email this page to a colleague
When do Somatuline patents expire, and what generic alternatives are available?
Somatuline is a drug marketed by Ipsen Pharma and is included in one NDA.
The generic ingredient in SOMATULINE is lanreotide acetate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanreotide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Somatuline
A generic version of SOMATULINE was approved as lanreotide acetate by INVAGEN PHARMS on December 17th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SOMATULINE?
- What are the global sales for SOMATULINE?
- What is Average Wholesale Price for SOMATULINE?
Summary for SOMATULINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Prices: | Drug price information for SOMATULINE |
| DailyMed Link: | SOMATULINE at DailyMed |
US Patents and Regulatory Information for SOMATULINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-001 | Aug 30, 2007 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-002 | Aug 30, 2007 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-003 | Aug 30, 2007 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
